Table 6 Three-year PFS, OS, LRFS, DMFS based on different IC regimens in III-IVb patients
TPF (%) n = 772 | PF (%) n = 340 | TP (%) n = 242 | P value | |
|---|---|---|---|---|
Progression-free survival | ||||
Failures | 108(14.0%) | 42(22.6%) | 47 (19.4%) | 0.127 |
Rate at 3 years | 82.4% (78.9–85.9) | 77.4% (72.3–82.5) | 73.8% (66.7–80.9) | |
Overall survival | ||||
Deaths | 23(3.0%) | 32 (9.4%) | 9(3.7%) | 0.029 |
Rate at 3 years | 97.2% (95.6–98.8) | 92.1% (88.8–95.4) | 97.0% (93.9–100) | |
Locoregional relapse-free survival | ||||
Locoregional failure | 40(5.2%) | 30 (8.8%) | 15 (6.2%) | 0.835 |
Rate at 3 years | 92.5% (90.0–95.0) | 91.5% (88.0–95.0) | 91.7% (87.2–96.2) | |
Distant metastasis-free survival | ||||
Distant failures | 72(9.3%) | 53 (15.6%) | 33 (13.6%) | 0.103 |
Rate at 3 years | 88.4% (85.7–91.1) | 83.3% (78.8–87.8) | 80.7% (74.0–87.4) | |